Pfizer grants Medicus co-development rights to CD228-targeted ADC PF-08046031
read at Endpoints ↗DealNeutral
Pfizer announced it is transferring co-development rights for its CD228-targeted antibody-drug conjugate, PF-08046031, to Medicus Pharma.
The ADC, originally discovered by Seagen, will now be advanced by Medicus, potentially speeding up its clinical development timeline.
In the same briefing, RevMed provided an update on its lung cancer data, though specific results were not disclosed. The release also mentioned news about Novartis without further detail.
source
This writeup was produced by pharmadog from original reporting by Endpoints.
Original headline: “Pfizer shares ADC rights with Medicus; RevMed updates lung cancer data”
read at Endpoints ↗80 words · retrieved Sep 3
comments(0)
5-min edit window · permanent after that